AIM
AYTU icon

Alambic Investment Management’s AYTU BioPharma AYTU Stock Holding History

Alambic Investment Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-66
Closed -$36K – 313
2018
Q3 		$36K Buy
+66
New +$61.1K 0.03% 273

Other funds holding AYTU

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Alambic Investment Management's AYTU Position: Q4 2018 in Review

Alambic Investment Management sold out of AYTU BioPharma (AYTU) in Q4 2018, closing a stake of 66 shares — an estimated $36K sold.

Alambic Investment Management first reported a position in AYTU in Q3 2018 and held it in 1 quarter. The position peaked at $36K in Q3 2018. 10 funds tracked by Wall St. Rank hold AYTU as of Q4 2018.

  • Alambic Investment Management reported no remaining AYTU BioPharma position as of Q4 2018 after selling out during the quarter.
  • Alambic Investment Management sold 66 AYTU BioPharma shares in Q4 2018, an estimated $36K.
  • Alambic Investment Management first reported a position in AYTU BioPharma in Q3 2018 and held it in 1 quarter.
  • Alambic Investment Management's AYTU BioPharma position peaked at $36K in Q3 2018.
  • 10 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2018.

Based on Alambic Investment Management's 13F filing for Q4 2018, filed 12 Feb 2019.